Shots:
- The P-III IMpower010 involves assessing Tecentriq + BSC in 1,005 participants in a ratio (1:1) with Stage IB-IIIA NSCLC, following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
- Results: 34% reduction in risk of death in people with Stage II-IIIA NSCLC. In the larger population of all randomized Stage II-IIIA study patients showed a 21% reduction in risk of disease recurrence or death after a median follow-up of 32.2mos, DFS (42.3mos. vs 35.3mos.), no new safety signals were observed
- Tecentriq is the first and only cancer immunotherapy to show positive P-III results in the adjuvant lung cancer setting
Click here to read full press release/ article | Ref: Businesswire | Image: Center for Health Journalism
The post Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC first appeared on PharmaShots.
